NCT04819347View on ClinicalTrials.gov

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

PHASE2UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

December 1, 2022

Conditions
HIV/AIDS
Interventions
DRUG

Albuvirtide

Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)

DRUG

3BNC117

Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Frontier Biotechnologies Inc.

INDUSTRY